PULMONARY FIBROSIS

This study is testing a new inhaled treatment for pulmonary fibrosis, a condition that causes lung scarring. The treatment uses tiny fat bubbles (liposomes) coated with a special substance to target harmful cells in the lungs. The goal is to reduce inflammation and scarring. The …

This early-stage trial tests a new treatment for pulmonary fibrosis, a disease that scars the lungs and makes breathing hard. Seven people will inhale a protein made from donated fat cells every 3 days for 7 doses. The study checks if the treatment is safe and improves breathing …

This study tests whether the drug sirolimus can prevent long-term lung scarring (pulmonary fibrosis) in people hospitalized with severe COVID-19 pneumonia. About 60 adults who need extra oxygen will receive sirolimus to see if it reduces the chance of developing fibrosis. The goa…

This study collects blood, DNA, and lung tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. Researchers aim to uncover the biological causes of this lung-scarring disease. No treatments or interventions are tested; the goal is purely …

This study follows 500 adults who had COVID-19 to learn about long-term health issues like breathing trouble, tiredness, and lung damage. Researchers will track recovery patterns and identify who is most at risk for lasting problems. No new treatments are tested; the goal is to b…

This study aims to understand how common short telomeres are in Israeli adults with fibrotic interstitial lung disease (lung scarring). Researchers will take blood samples from 100 participants and follow their health for two years. No new treatments are tested; the goal is to ga…

This study looks at how often severe COVID-19 leads to lung scarring (pulmonary fibrosis) and what factors increase that risk. Researchers will follow 200 intensive care patients to see if scarring affects survival and recovery. The goal is to better understand and predict this c…

This study examines how well immunotherapy works in people who have both lung cancer and pulmonary fibrosis (lung scarring). Researchers will review medical records of 200 patients and analyze tumor tissue at a cellular level to understand why some respond differently. The goal i…

This study follows 157 adults with pulmonary fibrosis in Spain who are taking nintedanib and taking part in a patient support program called Balance. Researchers want to see how satisfied patients are with the program and how their quality of life, mood, and symptoms change over …

This study looks at lung tissue from 80 people with pulmonary fibrosis to find unique genetic markers linked to scarring. By analyzing gene activity in the tissue, researchers hope to uncover how the lung gets damaged. The goal is to pave the way for better diagnosis and treatmen…